FDA
-
-
-
-
-
-
-
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
-
-
-
-
-
-
-
Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights
-
-
-
-
-
-
-
Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis
-
-
-
-
-
-
-
Evelo Biosciences Announces EDP1815 to Advance into Phase 2/3 TACTIC-E COVID-19 Trial
-
-
-
-
-
-
-
Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration
-
-
-
-
-
-
-
Evelo Biosciences Reports First Quarter 2018 Financial Results and Recent Business Highlights
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

